Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCSK9 inhibitors in high-risk coronary plaques (FLAVOUR IV)
NCT06863545Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Apr 2025
- Primary completion
- Apr 2030
- Countries
- 2
01
Overview
Randomised, double-blind trial in coronary artery disease (CAD), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Major adverse cardiac and cerebrovascular events at 24 months. Started Apr 2025; status: recruiting.
02
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT06863545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06863545.